The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin

Author： He Y.-L.   Sabo R.   Campestrini J.   Wang Y.   Ligueros-Saylan M.   Lasseter K.   Dilzer S.   Howard D.   Dole W.  

Publisher： Springer Publishing Company

ISSN： 0031-6970

Source： European Journal of Clinical Pharmacology, Vol.63, Iss.7, 2007-07, pp. : 677-686

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties

By Ahrén Bo  

Expert Opinion on Investigational Drugs, Vol. 15, Iss. 4, 2006-04 ,pp. : 431-442

Informa Healthcare

Access to resources Recommend Favorite

Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes

By Stein Stephanie A   Lamos Elizabeth M   Davis Stephen N  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 10, Iss. 4, 2014-04 ,pp. : 599-608

Informa Healthcare

Access to resources Recommend Favorite

Emerging Drug Candidates of Dipeptidyl Peptidase IV (DPP IV) Inhibitor Class for the Treatment of Type 2 Diabetes

By  

Current Drug Targets, Vol. 10, Iss. 1, 2009-01 ,pp. : 71-87

Bentham Science Publishers

Access to resources Recommend Favorite

Azetidine-Based Inhibitors of Dipeptidyl Peptidase IV (DPP IV)

By  

Current Topics in Medicinal Chemistry, Vol. 7, Iss. 6, 2007-03 ,pp. : 597-608

Bentham Science Publishers

Access to resources Recommend Favorite

The Therapeutic Potential of Inhibitors of Dipeptidyl Peptidase IV (DPP IV) and Related Proline-Specific Dipeptidyl Aminopeptidases

By  

Current Medicinal Chemistry, Vol. 12, Iss. 8, 2005-04 ,pp. : 971-998

Bentham Science Publishers

Access to resources Recommend Favorite